Zacks Research Brokers Increase Earnings Estimates for Bausch Health Companies Inc. (TSE:BHC)

Bausch Health Companies Inc. (TSE:BHC) – Investment analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for Bausch Health Companies in a report released on Thursday, May 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.26 for the quarter, up from their prior forecast of $1.25. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.53 EPS, FY2025 earnings at $5.70 EPS, Q1 2026 earnings at $1.45 EPS and FY2026 earnings at $6.82 EPS.

Separately, Royal Bank of Canada increased their price objective on Bausch Health Companies from C$8.00 to C$9.00 and gave the stock a “sector perform” rating in a research report on Friday, February 23rd.

Bausch Health Companies Trading Down 0.1 %

Shares of Bausch Health Companies stock opened at C$8.71 on Friday. The company’s 50-day moving average price is C$11.66 and its 200-day moving average price is C$11.09. The company has a market cap of C$3.19 billion, a price-to-earnings ratio of -5.15, a PEG ratio of 0.21 and a beta of 0.90. Bausch Health Companies has a 12-month low of C$8.62 and a 12-month high of C$15.43. The company has a current ratio of 1.23, a quick ratio of 0.58 and a debt-to-equity ratio of 7,583.76.

Bausch Health Companies (TSE:BHC) last issued its earnings results on Thursday, May 2nd. The company reported C$0.80 EPS for the quarter, missing the consensus estimate of C$1.02 by C($0.22). The company had revenue of C$2.90 billion during the quarter, compared to the consensus estimate of C$2.98 billion. Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 5.07%.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.